{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:11:55Z","timestamp":1784826715533,"version":"3.55.0"},"reference-count":21,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Immunoglobulin A nephropathy (IgAN) is one of the most common causes of primary glomerulonephritis and follows a \u2018four hit\u2019 model of pathogenesis. Novel treatments show promise in treating either the early insults described by this model or the subsequent inflammatory reaction. This case report describes a man in his 50s who received bimekizumab for his HLA B27-positive spondylarthritis in the setting of IgAN. His background history includes bilateral enthesitis of the ankles, bilateral Achilles tendonitis, peripheral arteritis and anterior uveitis. 6 months after starting on bimekizumab, his renal parameters improved with a reduction in his albuminuria and an increase in his estimated glomerular filtration rate (eGFR). This improvement may be explained by bimekizumab\u2019s dual blockade of IL-17 A and F, blunting the inflammatory pathways relevant to IgAN although causality cannot be inferred from a single case.<\/jats:p>","DOI":"10.1136\/bcr-2026-272393","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:45:21Z","timestamp":1784825121000},"page":"e272393","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney function recovery in immunoglobulin A nephropathy patient following bimekizumab therapy"],"prefix":"10.1136","volume":"19","author":[{"given":"Benjamin","family":"Zhang","sequence":"first","affiliation":[{"name":"Medicine, Bond University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4133-3989","authenticated-orcid":false,"given":"Hanish","family":"Bagga","sequence":"additional","affiliation":[{"name":"Brisbane Rheumatology, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6535-5601","authenticated-orcid":false,"given":"Richard Alexander","family":"Baer","sequence":"additional","affiliation":[{"name":"Medicine, Wesley Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072309451230000_19.7.e272393.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-024-03555-5","article-title":"Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries","volume":"25","author":"Zaidi","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026072309451230000_19.7.e272393.2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011050464"},{"key":"2026072309451230000_19.7.e272393.3","doi-asserted-by":"crossref","first-page":"151564","DOI":"10.1016\/j.semnephrol.2025.151564","article-title":"IgA Nephropathy: Epidemiology and Disease Risk Across the World","volume":"44","author":"Ghaddar","year":"2024","journal-title":"Semin Nephrol"},{"key":"2026072309451230000_19.7.e272393.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"2026072309451230000_19.7.e272393.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.04.021"},{"key":"2026072309451230000_19.7.e272393.6","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","article-title":"Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study","volume":"6","author":"Bagchi","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026072309451230000_19.7.e272393.7","doi-asserted-by":"publisher","DOI":"10.1081\/JDI-100104732"},{"key":"2026072309451230000_19.7.e272393.8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1242241","article-title":"Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy","volume":"10","author":"Dong","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026072309451230000_19.7.e272393.9","first-page":"4103","article-title":"Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single\u2011center cohort study","volume":"18","author":"Tang","year":"2018","journal-title":"Mol Med Report"},{"key":"2026072309451230000_19.7.e272393.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.004"},{"key":"2026072309451230000_19.7.e272393.11","doi-asserted-by":"crossref","first-page":"151573","DOI":"10.1016\/j.semnephrol.2025.151573","article-title":"The Rapidly Changing Treatment Landscape of IgA Nephropathy","volume":"44","author":"Cheung","year":"2024","journal-title":"Semin Nephrol"},{"key":"2026072309451230000_19.7.e272393.12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s11596-025-00068-6","article-title":"Crosstalk Between Th17 Cells and Renal Tubular Epithelial Cells Promotes Fibrotic Progression in IgA Nephropathy","volume":"45","author":"Zhou","year":"2025","journal-title":"Curr Med Sci"},{"key":"2026072309451230000_19.7.e272393.13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/0886022X.2017.1419972","article-title":"Interleukin-17 promotes the production of underglycosylated IgA1 in DAKIKI cells","volume":"40","author":"Lin","year":"2018","journal-title":"Ren Fail"},{"key":"2026072309451230000_19.7.e272393.14","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026072309451230000_19.7.e272393.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2026072309451230000_19.7.e272393.16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801042"},{"key":"2026072309451230000_19.7.e272393.17","first-page":"351","article-title":"Bimekizumab: The First FDA-Approved Dual IL-17A\/IL-17F Inhibitor for Plaque Psoriasis - A Comprehensive Literature Review","volume":"15","author":"Al Alshaikh","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"2026072309451230000_19.7.e272393.18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0971-4065.159303","article-title":"Th1, Th2 and Treg\/T17 cytokines in two types of proliferative glomerulonephritis","volume":"26","author":"Stangou","year":"2016","journal-title":"Indian J Nephrol"},{"key":"2026072309451230000_19.7.e272393.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-55425-7","article-title":"Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients","volume":"14","author":"Uriol-Rivera","year":"2024","journal-title":"Sci Rep"},{"key":"2026072309451230000_19.7.e272393.20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031219","article-title":"IgA nephropathy pathogenesis and therapy: Review & updates","volume":"101","author":"Habas","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026072309451230000_19.7.e272393.21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/1756-185X.14667","article-title":"Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis","volume":"26","author":"Ozince","year":"2023","journal-title":"Int J Rheum Dis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-272393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:45:23Z","timestamp":1784825123000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-272393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bcr-2026-272393"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-272393","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}